CA2368165A1 - Sels de carboxamide d'aminoimidazole utiles dans la prevention et le traitement des maladies du foie - Google Patents

Sels de carboxamide d'aminoimidazole utiles dans la prevention et le traitement des maladies du foie Download PDF

Info

Publication number
CA2368165A1
CA2368165A1 CA002368165A CA2368165A CA2368165A1 CA 2368165 A1 CA2368165 A1 CA 2368165A1 CA 002368165 A CA002368165 A CA 002368165A CA 2368165 A CA2368165 A CA 2368165A CA 2368165 A1 CA2368165 A1 CA 2368165A1
Authority
CA
Canada
Prior art keywords
prevention
salts
treatment
liver diseases
aminoimidazole carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002368165A
Other languages
English (en)
Other versions
CA2368165C (fr
Inventor
Rashida A. Karmali
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tactical Therapeutics Inc
Original Assignee
Savvipharm Inc
Rashida A. Karmali
Tactical Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savvipharm Inc, Rashida A. Karmali, Tactical Therapeutics, Inc. filed Critical Savvipharm Inc
Publication of CA2368165A1 publication Critical patent/CA2368165A1/fr
Application granted granted Critical
Publication of CA2368165C publication Critical patent/CA2368165C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002368165A 1999-04-20 2000-04-20 Sels de carboxamide d'aminoimidazole utiles dans la prevention et le traitement des maladies du foie Expired - Fee Related CA2368165C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/295,639 1999-04-20
US09/295,639 US6184227B1 (en) 1995-07-21 1999-04-20 Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
PCT/US2000/010690 WO2000078311A1 (fr) 1999-04-20 2000-04-20 Sels de carboxamide d'aminoimidazole utiles dans la prevention et le traitement des maladies du foie

Publications (2)

Publication Number Publication Date
CA2368165A1 true CA2368165A1 (fr) 2000-12-28
CA2368165C CA2368165C (fr) 2009-07-07

Family

ID=23138586

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002368165A Expired - Fee Related CA2368165C (fr) 1999-04-20 2000-04-20 Sels de carboxamide d'aminoimidazole utiles dans la prevention et le traitement des maladies du foie

Country Status (7)

Country Link
US (1) US6184227B1 (fr)
EP (1) EP1178796B1 (fr)
JP (1) JP5073897B2 (fr)
AT (1) ATE516027T1 (fr)
AU (1) AU4651700A (fr)
CA (1) CA2368165C (fr)
WO (1) WO2000078311A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710086B1 (en) * 2000-02-25 2004-03-23 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
US20080000489A1 (en) * 2000-10-30 2008-01-03 Biohit Oyj Method and preparation for binding aldehydes in saliva
US20020110605A1 (en) * 2000-12-11 2002-08-15 Ryusuke Nakagiri Liver function protecting or improving agent
DE10124820A1 (de) 2001-05-21 2002-12-05 Heinrich Wieland Zusammensetzung und Verwendung von Substanzen zur Stabilisierung von schwefelhaltigen Aminosäuren im Blut
US20050281879A1 (en) * 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
CN102784396B (zh) * 2004-11-09 2015-07-29 希尔氏宠物营养品公司 抗氧化剂用于基因调节的用途
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
CN101107012A (zh) * 2004-11-24 2008-01-16 希尔氏宠物营养品公司 改进动物异生素物质肝清除率的方法
US8252742B2 (en) * 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
AU2005322887B2 (en) * 2004-12-30 2010-03-11 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
CA2593563A1 (fr) * 2005-01-05 2006-07-13 Magd Ahmed Kotb Abdalla Synthese de taurine, production et utilisation de celle-ci comme medicament
WO2006074416A1 (fr) * 2005-01-07 2006-07-13 Health Research Inc. 5-amino-4-imidazolecarboxamide riboside et sa nucléobase en tant qu'agents amplificateurs du transport et du métabolisme d'antifolates
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
US7601834B2 (en) * 2005-02-22 2009-10-13 Savvipharm Inc Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives
WO2008008380A1 (fr) * 2006-07-12 2008-01-17 Regents Of The University Of Minnesota Traitement thérapeutique combiné d'une addiction
CN102846620B (zh) * 2012-10-22 2014-07-16 于可田 一种具有解酒醒酒作用的组合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1210865B (de) 1962-03-05 1966-02-17 Fujisawa Pharmaceutical Co Verfahren zur Herstellung des 2, 6-dioxo-tetrahydropyrimidin-4-carbonsauren Salzes des 4-Amino-5-imidazolcarbonsaeureamids
FR2086266A1 (en) * 1970-04-23 1971-12-31 Selvi & C Lab Bioterapico Hepatic detoxicant amino-imidazolecarboxa-mido-ureidosuccinate
US3915982A (en) * 1973-01-31 1975-10-28 Kyowa Gas Chem Ind Co Ltd Imidazole derivatives and process for their preparation
HU190597B (en) * 1983-07-11 1986-09-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing synrtgetic pharmaceutical compositions
US5223503A (en) * 1991-04-29 1993-06-29 Eli Lilly And Company 6-substituted pyrido[2,3-d]pyrimidines as antineoplastic agents
US5728707A (en) * 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
ATE278399T1 (de) * 1995-07-21 2004-10-15 Savvipharm Inc Orotatsalze von 5-amino- oder substituierten amino-1,2,3-triazolen zur behandlung von neoplasmen

Also Published As

Publication number Publication date
JP2003526624A (ja) 2003-09-09
JP5073897B2 (ja) 2012-11-14
ATE516027T1 (de) 2011-07-15
EP1178796A1 (fr) 2002-02-13
CA2368165C (fr) 2009-07-07
WO2000078311A1 (fr) 2000-12-28
AU4651700A (en) 2001-01-09
US6184227B1 (en) 2001-02-06
EP1178796B1 (fr) 2011-07-13
EP1178796A4 (fr) 2004-07-14

Similar Documents

Publication Publication Date Title
CA2303498A1 (fr) Acides dioxocyclopentylhydroxamiques
WO2001066564A3 (fr) Inhibiteurs de gamma-sécrétase
CA2368165A1 (fr) Sels de carboxamide d'aminoimidazole utiles dans la prevention et le traitement des maladies du foie
WO2003053368A3 (fr) Derives de chalcone et leur utilisation dans le traitement de maladies
WO2004078712A3 (fr) Derives d'isoquinoline et leurs methodes d'utilisation
WO2001007432A3 (fr) Composes
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
CA2289717A1 (fr) Nouveau traitement de la constipation
WO2003053359A3 (fr) 1,3-bis-(phenyl-substitue)-2-propyne-1-ones et leur utilisation pour le traitement d'affections
WO1999063978A3 (fr) Methodes de traitement de l'infection microbienne et formulations therapeutiques prevues a cet effet
CA2343439A1 (fr) Compositions utiles pour le traitement des maladies du tissu conjonctif
AU3173301A (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
WO2003066597A3 (fr) Composes guanidino
AU3632600A (en) Compositions and methods for the treatment of immune related diseases
WO2003039453A3 (fr) Compositions de peroxyde de dibenzoyle pour le traitement de troubles dermatologiques, et procedes d'utilisation correspondants
WO1999012933A3 (fr) Derives de pyrrolopyrrolone en tant qu'inhibiteurs de neutrophile elastase
CA2267309A1 (fr) Utilisation de 1-hydroxy-2-pyridones pour le traitement d'infections cutanees
WO2001057042A3 (fr) Derives de pyrrole 4-pyridyl- et 2,4-pyrimidinyl-substitues et leur utilisation en pharmacie
ZA979647B (en) Heterocyclic compounds, compositions and uses.
EP1219296A4 (fr) Inhibiteurs de la production de sebum
AU2566101A (en) Compounds and methods for the treatment of pain
AU3434601A (en) Compositions and methods for the treatment of immune related diseases
WO2004048381A3 (fr) Nouveaux composes de pyrazoloazepine utilises en tant qu'agents pharmaceutiques
WO2003024996A3 (fr) Macrocycles antibacteriens
ZA979645B (en) Heterocyclic compounds, compositions and uses.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170420